Evidence map›Paper›PMID 26580606›Full record

ReviewInternational journal of molecular sciences2015

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors.

Xiaonan Zhang, Angelo de Milito, Maria Hägg Olofsson, Joachim Gullbo, Padraig D'Arcy, Stig Linder

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Frontiers in microbiology · 2020
    Article
  18. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.Journal of cancer research and clinical oncology · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaonan ZhangDepartment of Medical and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden. Xiaonan.Zhang@ki.se.
Angelo de MilitoDepartment of Oncology-Pathology, Karolinska Institute, SE-171 76 Stockholm, Sweden. Angelo.De-Milito@ki.se.
Maria Hägg OlofssonDepartment of Oncology-Pathology, Karolinska Institute, SE-171 76 Stockholm, Sweden. Maria.Hagg@ki.se.
Joachim GullboDepartment of Immunology, Genetics and Pathology, Section of Oncology, Uppsala University, 751 85 Uppsala, Sweden. joachim.gullbo@medsci.uu.se.
Padraig D'ArcyDepartment of Medical and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden. padraig.darcy@liu.se.
Stig LinderDepartment of Medical and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden. Stig.Linder@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The disorganized nature of tumor vasculature results in the generation of microenvironments characterized by nutrient starvation, hypoxia and accumulation of acidic metabolites. Tumor cell populations in such areas are often slowly proliferating and thus refractory to chemotherapeutical drugs that are dependent on an active cell cycle. There is an urgent need for alternative therapeutic interventions that circumvent growth dependency. The screening of drug libraries using multicellular tumor spheroids (MCTS) or glucose-starved tumor cells has led to the identification of several compounds with promising therapeutic potential and that display activity on quiescent tumor cells. Interestingly, a common theme of these drug screens is the recurrent identification of agents that affect mitochondrial function. Such data suggest that, contrary to the classical Warburg view, tumor cells in nutritionally-compromised microenvironments are dependent on mitochondrial function for energy metabolism and survival. These findings suggest that mitochondria may represent an "Achilles heel" for the survival of slowly-proliferating tumor cells and suggest strategies for the development of therapy to target these cell populations.

Indexed as

AnimalsAntineoplastic AgentsCell ProliferationDrug DiscoveryDrug Resistance, NeoplasmDrug Screening Assays, AntitumorEnergy MetabolismGlucoseHumansHypoxiaMitochondriaMolecular Targeted TherapyNeoplasmsNeoplastic Stem CellsOxidative PhosphorylationResting Phase, Cell CycleAntineoplastic AgentsGlucosecancer therapyglucosemitochondriamulticellular tumor spheroidsoxidative phosphorylationsolid tumor

Identifiers

PMID26580606
PMCPMC4661878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.